Radiation Oncology Journal

  • 제37권3호
  • /
  • Pages.149-155
  • /
  • 2019
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Local ablative radiotherapy for oligometastatic non-small cell lung cancer

  • Suh, Yang-Gun (Proton Therapy Center, Research Institute and Hospital, National Cancer Center) ;
  • Cho, Jaeho (Department of Radiation Oncology, Yonsei University College of Medicine)
  • 투고 : 2019.09.19
  • 심사 : 2019.09.27
  • 발행 : 2019.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

In metastatic non-small cell lung cancer (NSCLC), the role of radiotherapy (RT) has been limited to palliation to alleviate the symptoms. However, with the development of advanced RT techniques, recent advances in immuno-oncology therapy targeting programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) and targeted agents for epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation allowed new roles of RT in these patients. Within this metastatic population, there is a subset of patients with a limited number of sites of metastatic disease, termed as oligometastasis that can achieve long-term survival from aggressive local management. There is no consensus on the definition of oligometastasis; however, most clinical trials define oligometastasis as having 3 to 5 metastatic lesions. Recent phase II randomized clinical trials have shown that ablative RT, including stereotactic ablative body radiotherapy (SABR) and hypofractionated RT, to primary and metastatic sites improved progression-free survival (PFS) and overall survival (OS) in patients with oligometastatic NSCLC. The PEMBRO-RT study, a randomized phase II study comparing SABR prior to pembrolizumab therapy and pembrolizumab therapy alone, revealed that the addition of SABR improved the overall response, PFS, and OS in patients with advanced NSCLC. The efficacy of RT in oligometastatic lung cancer has only been studied in phase II studies; therefore, large-scale phase III studies are needed to confirm the benefit of local ablative RT in patients with oligometastatic NSCLC. Local intensified RT to primary and metastatic lesions is expected to become an important treatment paradigm in the near future in patients with metastatic lung cancer.

키워드

참고문헌

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. https://doi.org/10.3322/caac.21492
  2. Jung KW, Won YJ, Kong HJ, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat 2019;51:417-30. https://doi.org/10.4143/crt.2019.138
  3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. https://doi.org/10.1056/NEJMoa061884
  4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. https://doi.org/10.1056/NEJMoa0810699
  5. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012;83:878-86. https://doi.org/10.1016/j.ijrobp.2011.08.036
  6. Palma DA, Salama JK, Lo SS, et al. The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol 2014;11:549-57. https://doi.org/10.1038/nrclinonc.2014.96
  7. Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-smallcell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016;17:1672-82. https://doi.org/10.1016/S1470-2045(16)30532-0
  8. Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 2018;4:e173501. https://doi.org/10.1001/jamaoncol.2017.3501
  9. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92. https://doi.org/10.1056/NEJMoa1113205
  10. Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med 2017;376:2109-21. https://doi.org/10.1056/NEJMoa1616288
  11. Brannon AR, Vakiani E, Sylvester BE, et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 2014;15:454. https://doi.org/10.1186/s13059-014-0454-7
  12. Goto T, Hirotsu Y, Mochizuki H, et al. Mutational analysis of multiple lung cancers: discrimination between primary and metastatic lung cancers by genomic profile. Oncotarget 2017;8:31133-43. https://doi.org/10.18632/oncotarget.16096
  13. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011;29:2972-7. https://doi.org/10.1200/JCO.2010.33.3906
  14. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009;9:302-12. https://doi.org/10.1038/nrc2627
  15. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability: an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010;11:220-8. https://doi.org/10.1038/nrm2858
  16. Turajlic S, Swanton C. Metastasis as an evolutionary process. Science 2016;352:169-75. https://doi.org/10.1126/science.aaf2784
  17. Correa RJ, Salama JK, Milano MT, Palma DA. Stereotactic body radiotherapy for oligometastasis: opportunities for biology to guide clinical management. Cancer J 2016;22:247-56. https://doi.org/10.1097/PPO.0000000000000202
  18. Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997;113:37-49. https://doi.org/10.1016/S0022-5223(97)70397-0
  19. Sternberg DI, Sonett JR. Surgical therapy of lung metastases. Semin Oncol 2007;34:186-96. https://doi.org/10.1053/j.seminoncol.2007.03.004
  20. Timmerman RD, Bizekis CS, Pass HI, et al. Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin 2009;59:145-70. https://doi.org/10.3322/caac.20013
  21. Curley SA, Marra P, Beaty K, et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004;239:450-8. https://doi.org/10.1097/01.sla.0000118373.31781.f2
  22. Kawamura M, Izumi Y, Tsukada N, et al. Percutaneous cryoablation of small pulmonary malignant tumors under computed tomographic guidance with local anesthesia for nonsurgical candidates. J Thorac Cardiovasc Surg 2006;131:1007-13. https://doi.org/10.1016/j.jtcvs.2005.12.051
  23. Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010;76:326-32. https://doi.org/10.1016/j.ijrobp.2009.09.042
  24. Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009;27:1579-84. https://doi.org/10.1200/JCO.2008.19.6386
  25. Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol 2010;5:1091-9. https://doi.org/10.1097/JTO.0b013e3181de7143
  26. Mendez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol 2006;45:831-7. https://doi.org/10.1080/02841860600897934
  27. Holy R, Piroth M, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 2011;187:245-51. https://doi.org/10.1007/s00066-011-2192-z
  28. Chawla S, Chen Y, Katz AW, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys 2009;75:71-5. https://doi.org/10.1016/j.ijrobp.2008.10.079
  29. Milano MT, Katz AW, Muhs AG, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 2008;112:650-8. https://doi.org/10.1002/cncr.23209
  30. Gerszten PC, Mendel E, Yamada Y. Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine (Phila Pa 1976) 2009;34(22 Suppl):S78-92. https://doi.org/10.1097/BRS.0b013e3181b8b6f5
  31. Schanne DH, Heitmann J, Guckenberger M, Andratschke NHJ. Evolution of treatment strategies for oligometastatic NSCLC patients: a systematic review of the literature. Cancer Treat Rev 2019;80:101892. https://doi.org/10.1016/j.ctrv.2019.101892
  32. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019;393:2051-8. https://doi.org/10.1016/s0140-6736(18)32487-5
  33. Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 2019;37:1558-65. https://doi.org/10.1200/jco.2019.37.15_suppl.1558
  34. Wu YL, Planchard D, Lu S, et al. Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol 2019;30:171-210. https://doi.org/10.1093/annonc/mdy554
  35. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46. https://doi.org/10.1016/S1470-2045(11)70393-X
  36. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34. https://doi.org/10.1200/JCO.2012.44.2806
  37. Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 2015;26:1883-9. https://doi.org/10.1093/annonc/mdv270
  38. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113-25. https://doi.org/10.1056/NEJMoa1713137
  39. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011;17:1616-22. https://doi.org/10.1158/1078-0432.CCR-10-2692
  40. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-7. https://doi.org/10.1158/1078-0432.CCR-12-2246
  41. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-smallcell lung cancer. J Thorac Oncol 2012;7:1807-14. https://doi.org/10.1097/JTO.0b013e3182745948
  42. Xu Q, Zhou F, Liu H, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol 2018;13:1383-92. https://doi.org/10.1016/j.jtho.2018.05.019
  43. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011;22:2616-24. https://doi.org/10.1093/annonc/mdr489
  44. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81. https://doi.org/10.1038/nm.2658
  45. Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin 2006;22:561-73. https://doi.org/10.1185/030079906X89847
  46. Lee Y, Shim HS, Park MS, et al. High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin Cancer Res 2012;18:1760-8. https://doi.org/10.1158/1078-0432.CCR-11-2582
  47. Tseng JS, Yang TY, Chen KC, Hsu KH, Chen HY, Chang GC. Retrospective study of erlotinib in patients with advanced squamous lung cancer. Lung Cancer 2012;77:128-33. https://doi.org/10.1016/j.lungcan.2012.02.012
  48. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64. https://doi.org/10.1038/nrc3239
  49. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35. https://doi.org/10.1056/NEJMoa1504627
  50. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. https://doi.org/10.1016/s0140-6736(15)01281-7
  51. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated nonsmall-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-46. https://doi.org/10.1016/S0140-6736(16)00587-0
  52. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive nonsmall-cell lung cancer. N Engl J Med 2016;375:1823-33. https://doi.org/10.1056/NEJMoa1606774
  53. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-smallcell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65. https://doi.org/10.1016/S0140-6736(16)32517-X
  54. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379:2342-50. https://doi.org/10.1056/NEJMoa1809697
  55. Bauml JM, Mick R, Ciunci C, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial. JAMA Oncol 2019 Jul 11 [Epub]. https://doi.org/10.1001/jamaoncol.2019.1449.
  56. Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRORT phase 2 randomized clinical trial. JAMA Oncol 2019 Jul 11 [Epub]. https://doi.org/10.1001/jamaoncol.2019.1478.
  57. Conibear J, Chia B, Ngai Y, et al. Study protocol for the SARON trial: a multicentre, randomized controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open 2018;8:e020690. https://doi.org/10.1136/bmjopen-2017-020690

피인용 문헌

  1. Oligorecurrence Non–small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography–Guided 125 I Seed Implantation vs. Second-Line Chemotherapy vol.10, 2019, https://doi.org/10.3389/fonc.2020.00470
  2. Neuroendocrine Carcinoma of Uterine Cervix: Stereotactic Radiotherapy for Brain Metastasis and Stereotactic Body Radiotherapy for Renal and Pancreatic Metastases vol.12, pp.6, 2019, https://doi.org/10.7759/cureus.8869
  3. Pulmonary artery coil embolisation prevented tumour progression in a patient with advanced squamous cell lung carcinoma vol.125, pp.3, 2019, https://doi.org/10.1080/03009734.2020.1753863
  4. Small cell lung cancer with thyroid gland oligometastasis: A case report vol.12, pp.3, 2019, https://doi.org/10.1111/1759-7714.13740